See trend so far
1. NCE is seems more likely given management giveup on 5 year NCE hope after October no decision as they think no decision hurt them most yet FDA delay again which mean FDA still consider Amerin argument for NCE and hoping additional patents getting issued will help justify it.
2. More patents getting issue which make NCE mute point except for additional premium company get with Buyout.
3. Lovaza manufacturer buyout where generic soon comming on market show how valuable AMRN is.
4. Company yet to higher sales rep and all other news give idea what is likely to happen.
After No.3 News, I would not suprise if big pharma offer $35 without NCE status.
Only possible bad news in near term is Company announce hiring sales reps. In My opinion they should have hire atleast 30% of need by now, atleast 70% by dec to launch by Jan end. Given they keep delaying means, there is something else on management/board member mind that we don't know yet.